Avvio Medical, Inc. Market Research Report

Background

Company Overview

Avvio Medical, Inc., formerly known as Applaud Medical, is a privately held medical technology company headquartered in San Francisco, California. Established in 2014, the company is dedicated to revolutionizing the treatment of urinary stone disease through innovative, minimally invasive solutions. Avvio Medical's mission is to enhance patient experiences, reduce healthcare costs, and expand access to care by offering rapid, office-based treatments that eliminate the need for general anesthesia or X-ray imaging.

Mission and Vision

Avvio Medical envisions a world free from the detrimental effects of excess biomineralization in the body, aiming to provide the safest and most effective treatments for urinary stone disease. The company's mission is to offer patients and healthcare professionals a fast, minimally invasive solution for treating urinary stone disease in various clinical or outpatient settings, eliminating the routine need for anesthesia or X-ray imaging.

Key Strategic Focus

Core Objectives

Avvio Medical's primary objective is to transform the standard of care for urinary stone disease by developing and commercializing innovative, non-invasive treatment technologies that improve patient outcomes and streamline healthcare delivery.

Areas of Specialization

The company specializes in the development of the Enhanced Lithotripsy System (ELS), which utilizes microbubble-enhanced acoustic cavitation lithotripsy to treat kidney stones. This technology enables treatments to be performed in outpatient and office-based settings without the need for general anesthesia or fluoroscopy.

Key Technologies Utilized

Microbubble-Enhanced Acoustic Cavitation Lithotripsy: A proprietary technology that employs low-pressure ultrasound to activate calcium-seeking microbubbles, creating micro-jets that fragment kidney stones.

Primary Markets Targeted

Avvio Medical targets the global market for kidney stone treatments, focusing on outpatient clinics, ambulatory surgery centers (ASCs), and rural healthcare settings where access to traditional operating rooms and specialized equipment may be limited.

Financials and Funding

Funding History

As of the latest available data, Avvio Medical has raised a total of $38.28 million in funding. The most recent funding round occurred approximately one year ago, raising $7.14 million.

Notable Investors

In November 2024, KMAK Capital, a family office focused on values-based strategic investments, announced a strategic investment in Avvio Medical to advance kidney stone treatment innovation.

Utilization of Capital

The capital raised is intended to support the continued development and commercialization of Avvio Medical's Enhanced Lithotripsy System, including clinical trials, regulatory approvals, and market expansion efforts.

Pipeline Development

Key Pipeline Candidates

Enhanced Lithotripsy System (ELS): A non-invasive treatment device for kidney stones that utilizes microbubble-enhanced acoustic cavitation lithotripsy.

Stages of Development

Clinical Trials: Avvio Medical has initiated a pivotal clinical trial for the ELS in the United States under an active Investigational Device Exemption (IDE). The first patients were treated using the ELS in May 2025, marking the official start of the clinical trial.

Target Conditions

Kidney Stones: Specifically targeting ureteral stones, with the aim to provide a minimally invasive, anesthesia-free treatment option.

Anticipated Milestones

FDA Breakthrough Device Designation: In October 2025, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the ELS, recognizing its potential to improve patient outcomes and expand access to minimally invasive kidney stone care.

Commercial Launch: Avvio Medical plans to launch the ELS commercially in the U.S. market in 2026, following FDA clearance.

Technological Platform and Innovation

Proprietary Technologies

Microbubble-Enhanced Acoustic Cavitation Lithotripsy: A proprietary technology that employs low-pressure ultrasound to activate calcium-seeking microbubbles, creating micro-jets that fragment kidney stones.

Significant Scientific Methods

Low-Pressure Ultrasound Activation: Utilizing low-pressure ultrasound waves to target and activate microbubbles, facilitating the fragmentation of kidney stones.

Leadership Team

Key Executives

Paul Molloy: Chief Executive Officer (CEO)

Professional Background: Experienced CEO and General Manager with extensive global venture capital and private equity relationships. Paul has participated in two IPOs and exited three of his last four firms as CEO. He managed Teleflex’s largest division (Arrow Vascular) from 2011-2013 with a $700M P&L.

Greg Johnstone: Chief Financial Officer (CFO)

Professional Background: Over 25 years of experience in medical device, diagnostics, and technology companies. Greg has served as CFO for numerous innovative and successful companies, including Attune Medical, Mindtribe, Auxogyn, and Sensant Corp. He has raised over $300M in financing and guided companies through all phases, including founding, development, commercialization, and successful exit.

Rohit Girotra: Vice President of Product Development

Professional Background: Over 17 years of medical device product development experience, taking Class I, II, and III devices from concept to commercialization. Rohit was most recently the co-founder and Director of R&D at Tusker Medical, where he led product development of the Tula system.

Susie Lahey: Vice President of Corporate Administration & Human Resources

Professional Background: Over 20 years of experience in administrative and HR leadership roles at various medical device companies. Susie is well-versed in the spectrum of duties associated with emerging companies and is passionate about driving employee engagement and building a diverse and inclusive workforce.

Louis Marcoux: Vice President of Regulatory, Quality & Clinical Affairs

Professional Background: Over 20 years of experience establishing robust quality systems and navigating complex regulatory pathways, both domestically and globally. Louis has held senior roles within Marketing and Regulatory Affairs at NeoTract and supported the global launch of the CoolSculpting System at ZELTIQ Aesthetics.

Competitor Profile

Market Insights and Dynamics

The global kidney stone treatment market is experiencing growth due to increasing incidence rates and advancements in minimally invasive procedures. The market is characterized by a shift towards outpatient treatments that reduce costs and improve patient recovery times.

Competitor Analysis

Boston Scientific Corporation: A leading medical device company offering a range of urology products, including lithotripsy devices.

Cook Medical: Provides a variety of urology products, including stone management devices.

Olympus Corporation: Offers endoscopic equipment and stone management solutions in the urology sector.

Strategic Collaborations and Partnerships

Avvio Medical's partnership with KMAK Capital in November 2024 is a significant collaboration aimed at advancing kidney stone treatment innovation.

Operational Insights

Avvio Medical's Enhanced Lithotripsy System offers a competitive advantage by enabling kidney stone treatments in outpatient and office-based settings without the need for general anesthesia or fluoroscopy. This approach reduces procedural costs and recovery times, positioning the company favorably in the market.

Strategic Opportunities and Future Directions

Avvio Medical plans to leverage its FDA Breakthrough Device Designation to expedite the development and commercialization of the Enhanced Lithotripsy System, aiming for a U.S. market launch in 2026. The company is also exploring international expansion opportunities to broaden access to its innovative treatment solutions.